First, I would like to report that I have tried the ND2’s. In my opinion, albeit subjective, the active substance is a phenethylamine, and probably an amphetamine analogue. The reason I say this is due to the increased duration of effect, and that it had a comedown that was equivalent to that of an 8-day meth binge (and this was only after one sitting of 3 ND2’s). Further to this, the chemical appeared to have a strong norepinephrine/epinephrine activity, mild dopaminergic activity, and little to no seretonergic activity.
Second, with regard to the old products, it would appear that Customs feel that they have the right to prevent these substances from being imported into states where the substances are not scheduled and there are no analogue laws – and thus legal? Specifically, Customs have determined that the ingredients are ‘drugs’, as defined in the Customs (Prohibited Imports) Regulations 1956, Regulation 5, which includes derivatives of substances which are scheduled drugs in the regulation.
According to the Customs (Prohibited Imports) Regulations 1956, Regulation 5(20), a derivative is defined as being “any substance chemically derived from the isomer or mixture of isomers and from which the isomer or mixture of isomers may be regenerated, and includes a salt of the isomer or mixture of isomers”. However, I suspect that this reasoning is erroneous, though hinges on the definition of derivative.
I believe that the substances contained within the neo range cannot/were not derived from chemicals that are scheduled within the act. Further to this, from my understanding, the regeneration of the products into isomers of any items scheduled in the act is not feasible
Specifically, Dimethylcathinone (Metamfepramone) is not pharmacologically derived from Diethylcathinone (Amfepramone), but is synthesised using α- bromopropiophenone (which can be derived from propiophenone) and dimethylamine, both chemicals that are not listed in Schedule 4 of the act. Further, the reduction of Dimethylcathinone to Diethylcathinone is pharmacologically implausible. Rather, if one was wishing to synthesise Diethylcathinone, he or she would use α- bromopropiophenone and diethylamine.
Do you think that what I am arguing here is correct?
Also, I was wondering whether anybody might provide some information on the precursor chemicals necessary for the synthesis of Phthalimidopropiophenenone and 4-Methyl-Methcathinone, and whether the reduction of the substances into cathinone and methcathinone respectively, is plausible within the laboratory (not in vivo), as is being suggested by Customs?
Any assistance with these questions would be greatly appreciated. I have posted the same questions in advanced drug discussion as I thought that I might be sampling from a different population with regard to collecting this data.